2. Cell Cycle/DNA Damage Epigenetics Apoptosis
  3. HDAC Apoptosis
  4. HDAC-IN-92

HDAC-IN-92 is a pan-HDAC inhibitor with an IC50 of 12.58 µM in A2780 cells. HDAC-IN-92 demonstrates broad-spectrum, notable cytotoxic activity against a range of human cancer cell lines, including ovarian, liver, and breast carcinomas. HDAC-IN-92 causes apoptosis and demonstrates a notable decrease in tumor cell colony formation. HDAC-IN-92 inhibits the formation of blood vessels in the chick chorioallantoic membrane (CAM). HDAC-IN-92 exhibits anti-tumor effect in a 4T1 tumor-bearing mouse model. HDAC-IN-92 can be used for research targeting solid tumor.

For research use only. We do not sell to patients.

HDAC-IN-92

HDAC-IN-92 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

HDAC-IN-92 Related Antibodies

Top Publications Citing Use of Products

View All HDAC Isoform Specific Products:

View All Isoforms
HDAC HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

HDAC-IN-92 is a pan-HDAC inhibitor with an IC50 of 12.58 µM in A2780 cells. HDAC-IN-92 demonstrates broad-spectrum, notable cytotoxic activity against a range of human cancer cell lines, including ovarian, liver, and breast carcinomas. HDAC-IN-92 causes apoptosis and demonstrates a notable decrease in tumor cell colony formation. HDAC-IN-92 inhibits the formation of blood vessels in the chick chorioallantoic membrane (CAM). HDAC-IN-92 exhibits anti-tumor effect in a 4T1 tumor-bearing mouse model. HDAC-IN-92 can be used for research targeting solid tumor[1].

In Vitro

HDAC-IN-92 (compound 6g) (18 h) demonstrates significant cytotoxicity in a broad panel of cancer cell lines, with IC50s of 22.17 μM (MCF-7), 8.46 μM (HepG2), 8.10 μM (A2780), 26.89 μM (A2780cis), 75.90 μM (HT29), and 14.11 μM (4T1)[1].
HDAC-IN-92 (18 h) demonstrates a correlation between its cytotoxicity against cancer cells and its pan-HDAC inhibitory activity, suggesting that its antitumor effect may be mediated by the inhibition of histone deacetylases[1].
HDAC-IN-92 (8.10 μM, 24 h) significantly promotes apoptosis, increasing the total apoptotic population from 1.82 % to 22.17 %, and inhibits cell migration in A2780 cells[1].
HDAC-IN-92 (22.17 μM, 10 days) remarkably reduces colony formation in MCF-7 cancer cells[1].
HDAC-IN-92 (5 μM, 96 h) inhibits CAM angiogenesis as effectively as Vorinostat (HY-10221), as evidenced by a marked reduction in branching points, tube number, and total tube length[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

HDAC-IN-92 Related Antibodies

Apoptosis Analysis[1]

Cell Line: A2780 cells
Concentration: 8.10 nM
Incubation Time: 24 h
Result: Increased percentage early and late apoptosis cells from 1.82 % of the control to 22.17 %.

Cell Proliferation Assay[1]

Cell Line: MCF-7 cells
Concentration: 22.17 nM
Incubation Time: 24 h
Result: Reduces colony formation in MCF-7 cancer cells.
In Vivo

HDAC-IN-92 (50 mg/kg, i.p., every other day for 21 days) inhibits tumor growth and is well-tolerated in 4T1 tumor-bearing BALB/c mouse model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female Balb/c mice (4-6 weeks old) injected subcutaneously with 4T1 cells[1]
Dosage: 50 mg/kg
Administration: i.p., every other day for 21 days
Result: Reduced tumor volume better than Vorinostat.
Exerted no significant effects on the body weight or survival rates of mice.
Induced tumor cell apoptosis without exhibiting toxicity in major organs.
Molecular Weight

384.43

Formula

C19H17FN4O2S
SMILES

O=C(NO)C1=CC=C(/N=C/C2=CN=C(SCC3=CC=CC(F)=C3)N2C)C=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

HDAC-IN-92 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

HDAC-IN-92HDACApoptosisHistone deacetylasespan-HDAC inhibitorapoptosiscolony formationblood vesselsVorinostat4T1 tumor-bearing mouse modelsolid tumorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
HDAC-IN-92
Cat. No.:
HY-175857
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.